The UK is now facing a significant problem in how it secures the country’s medicines’ supply chain after leaving the EU on 1 January 2021. But rather than view this as an insurmountable problem, FarmaTrust is calling on the UK government to be true to its word and deliver new Brexit benefits.
Covid-19 was an unpredictable so-called black swan event in 2020 and the second wave in Europe indicates we might need to live with the pandemic for a long time. Although the development of vaccines is a breakthrough, the impact of vaccination will be slow to materialise.
Microfluidic technologies are rapidly becoming the method of choice for micro- and nanoparticle production across a number of sectors, from cell biology research to drug development. This approach offers a number of advantages over traditional batch methods, including precise process control, enhanced reliability, and the ability to easily scale up production. Read more in C&I Magazine.